News >

Entrectinib Breaks Through With Japanese Approval for NTRK-Positive Tumors

Jason M. Broderick @jasoncology
Published: Tuesday, Jun 18, 2019

Dr. Sandra Horning

Sandra Horning, MD
Entrectinib (Rozlytrek) received its first regulatory approval, as Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the drug for the treatment of adult and pediatric patients with NTRK fusion–positive, advanced recurrent solid tumors.

The MHLW based its decision on data from the phase II STARTRK-2, phase I STARTRK-1, and phase I ALKA-372-001 trials, as well as findings from the phase I/II STARTRK-NG pediatric study. In STARTRK-2, specifically, entrectinib achieved an objective response rate (ORR) of 56.9% in patients with NTRK-positive solid tumors.1 The median duration of response was 10.4 months. Among patients with CNS metastases, the intracranial ORR (IC ORR) was 50%.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x